Unum Therapeutics, Inc. (Unum)

Oncology Corporate Profile

HQ Location

One Broadway 4th Floor
Cambridge, MA 2142

Company Description

Unum Therapeutics uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body's own immune system to fight cancer. Unum's lead program, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, recently entered Phase I clinical testing to assess safety and efficacy.

Website: http://www.unumrx.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
ATTCK20chimeric monoclonal antibody (inhibits CD20)Chronic Lymphocytic Leukemia (CLL)I
ATTCK20chimeric monoclonal antibody (inhibits CD20)Non-Hodgkin's Lymphoma (NHL)I

View additional information on product candidates here »

Source: http://www.unumrx.com/

Recent News Headlines

Unum Therapeutics Announces Recombinant DNA Advisory Committee’s (RAC) Unanimous Approval of Phase 1 Study Protocol to Evaluate ACTR Cell Therapy in Non-Hodgkin Lymphoma

12/14/2015 05:56 pm

(Yahoo! Finance) Dec 14, 2015 - Unum Therapeutics, a company developing a universal cellular immunotherapy to treat multiple cancers, announced today that it has received unanimous approval by the National Institute of Health’s (NIH) Recombinant DNA Advisory Committee (RAC) for its first U.S.-based clinical trial.